Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Get detailed information on Apixaban, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Those drugs were Eliquis, Jardiance ... noting that each price is for a 30-day supply: These negotiated drug prices will go into effect for Medicare Part D recipients on Jan. 1, 2026.

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also ...